Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Acute dosing of latrepirdine (Dimebon), a possible Alzheimer therapeutic, elevates extracellular amyloid-beta levels in vitro and in vivo.

Steele JW, Kim SH, Cirrito JR, Verges DK, Restivo JL, Westaway D, Fraser P, Hyslop PS, Sano M, Bezprozvanny I, Ehrlich ME, Holtzman DM, Gandy S.

Mol Neurodegener. 2009 Dec 17;4:51. doi: 10.1186/1750-1326-4-51.

2.
3.

Dimebon alters hippocampal amyloid pathology in 3xTg-AD mice.

Perez SE, Nadeem M, Sadleir KR, Matras J, Kelley CM, Counts SE, Vassar R, Mufson EJ.

Int J Physiol Pathophysiol Pharmacol. 2012;4(3):115-27.

4.

Memantine lowers amyloid-beta peptide levels in neuronal cultures and in APP/PS1 transgenic mice.

Alley GM, Bailey JA, Chen D, Ray B, Puli LK, Tanila H, Banerjee PK, Lahiri DK.

J Neurosci Res. 2010 Jan;88(1):143-54. doi: 10.1002/jnr.22172.

5.

Striking reduction of amyloid plaque burden in an Alzheimer's mouse model after chronic administration of carmustine.

Hayes CD, Dey D, Palavicini JP, Wang H, Patkar KA, Minond D, Nefzi A, Lakshmana MK.

BMC Med. 2013 Mar 26;11:81. doi: 10.1186/1741-7015-11-81.

6.

Latrepirdine improves cognition and arrests progression of neuropathology in an Alzheimer's mouse model.

Steele JW, Lachenmayer ML, Ju S, Stock A, Liken J, Kim SH, Delgado LM, Alfaro IE, Bernales S, Verdile G, Bharadwaj P, Gupta V, Barr R, Friss A, Dolios G, Wang R, Ringe D, Fraser P, Westaway D, St George-Hyslop PH, Szabo P, Relkin NR, Buxbaum JD, Glabe CG, Protter AA, Martins RN, Ehrlich ME, Petsko GA, Yue Z, Gandy S.

Mol Psychiatry. 2013 Aug;18(8):889-97. doi: 10.1038/mp.2012.106.

7.

Latrepirdine for Alzheimer's disease.

Chau S, Herrmann N, Ruthirakuhan MT, Chen JJ, Lanctôt KL.

Cochrane Database Syst Rev. 2015 Apr 21;(4):CD009524. doi: 10.1002/14651858.CD009524.pub2. Review.

PMID:
25897825
8.

The Effects of Latrepirdine on Amyloid-β Aggregation and Toxicity.

Porter T, Bharadwaj P, Groth D, Paxman A, Laws SM, Martins RN, Verdile G.

J Alzheimers Dis. 2016;50(3):895-905. doi: 10.3233/JAD-150790.

9.

Effects of Huanglian-Jie-Du-Tang and its modified formula on the modulation of amyloid-β precursor protein processing in Alzheimer's disease models.

Durairajan SS, Huang YY, Yuen PY, Chen LL, Kwok KY, Liu LF, Song JX, Han QB, Xue L, Chung SK, Huang JD, Baum L, Senapati S, Li M.

PLoS One. 2014 Mar 26;9(3):e92954. doi: 10.1371/journal.pone.0092954. Erratum in: PLoS One. 2014;9(7):e102923.

10.

Relationship between ubiquilin-1 and BACE1 in human Alzheimer's disease and APdE9 transgenic mouse brain and cell-based models.

Natunen T, Takalo M, Kemppainen S, Leskelä S, Marttinen M, Kurkinen KM, Pursiheimo JP, Sarajärvi T, Viswanathan J, Gabbouj S, Solje E, Tahvanainen E, Pirttimäki T, Kurki M, Paananen J, Rauramaa T, Miettinen P, Mäkinen P, Leinonen V, Soininen H, Airenne K, Tanzi RE, Tanila H, Haapasalo A, Hiltunen M.

Neurobiol Dis. 2016 Jan;85:187-205. doi: 10.1016/j.nbd.2015.11.005.

PMID:
26563932
11.

6-Methyluracil derivatives as acetylcholinesterase inhibitors for treatment of Alzheimer's disease.

Zueva IV, Semenov VE, Mukhamedyarov MA, Lushchekina SV, Kharlamova AD, Petukhova EO, Mikhailov AS, Podyachev SN, Saifina LF, Petrov KA, Minnekhanova OA, Zobov VV, Nikolsky EE, Masson P, Reznik VS.

Int J Risk Saf Med. 2015;27 Suppl 1:S69-71. doi: 10.3233/JRS-150694.

PMID:
26639718
12.
13.

Latrepirdine (dimebon) enhances autophagy and reduces intracellular GFP-Aβ42 levels in yeast.

Bharadwaj PR, Verdile G, Barr RK, Gupta V, Steele JW, Lachenmayer ML, Yue Z, Ehrlich ME, Petsko G, Ju S, Ringe D, Sankovich SE, Caine JM, Macreadie IG, Gandy S, Martins RN.

J Alzheimers Dis. 2012;32(4):949-67. doi: 10.3233/JAD-2012-120178.

14.

GEPT extract reduces Abeta deposition by regulating the balance between production and degradation of Abeta in APPV717I transgenic mice.

Tian J, Shi J, Zhang L, Yin J, Hu Q, Xu Y, Sheng S, Wang P, Ren Y, Wang R, Wang Y.

Curr Alzheimer Res. 2009 Apr;6(2):118-31.

PMID:
19355846
15.

Effects of growth hormone-releasing hormone on sleep and brain interstitial fluid amyloid-β in an APP transgenic mouse model.

Liao F, Zhang TJ, Mahan TE, Jiang H, Holtzman DM.

Brain Behav Immun. 2015 Jul;47:163-71. doi: 10.1016/j.bbi.2014.09.005.

16.
17.

Amyloid precursor protein processing and retinal pathology in mouse models of Alzheimer's disease.

Dutescu RM, Li QX, Crowston J, Masters CL, Baird PN, Culvenor JG.

Graefes Arch Clin Exp Ophthalmol. 2009 Sep;247(9):1213-21. doi: 10.1007/s00417-009-1060-3.

PMID:
19271231
19.

Changes in amyloid-β and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein.

Maia LF, Kaeser SA, Reichwald J, Hruscha M, Martus P, Staufenbiel M, Jucker M.

Sci Transl Med. 2013 Jul 17;5(194):194re2. doi: 10.1126/scitranslmed.3006446.

20.

Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse.

Chung E, Ji Y, Sun Y, Kascsak RJ, Kascsak RB, Mehta PD, Strittmatter SM, Wisniewski T.

BMC Neurosci. 2010 Oct 14;11:130. doi: 10.1186/1471-2202-11-130.

Items per page

Supplemental Content

Support Center